A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Hagen P, Sidana S, Parker T, Walker B, Sanchorawala V, Zonder J, Kourelis T, D'Souza A, Landau H, Rosenthal A, Hoering A, Ailawadhi S, Orlowski R. A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis. Blood 2024, 144: 3309.1-3309.1. DOI: 10.1182/blood-2024-208227.Peer-Reviewed Original ResearchAutologous stem cell transplantationNext generation flow cytometryStem cell transplantationOverall survivalConsolidation therapyAL amyloidCell transplantationASCT armLight chain (AL) amyloidosisSeverity of cardiac involvementFlow cytometryAL amyloid patientsDaratumumab to bortezomibTransplant related mortalityProgression free survivalHematologic response rateTwo-sided significance levelPlasma cell malignancyMulti-organ involvementDaratumumab maintenanceInduction therapyMRD negativityFree survivalIntergroup trialCardiac involvement